Petros Grivas, MD, PhD, discusses the role of single-agent and combination PARP inhibitor regimens in prostate cancer, as well as the importance of genetic testing in this setting, the role of adjuvant regimens in resected renal cell carcinoma, and more.
The Food and Drug Administration is reportedly expediting the review of Ambrx’s treatment for patients with metastatic, castration-resistant prostate cancer that has displayed promising early trial results.
Ambrx (AMAM) Announces ARX517 Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Experts have expressed concern that men with low-risk disease who are currently followed with active surveillance may be targeted with expensive therapies that have potentially serious side effects.